The Filing Desk

Black Diamond Therapeutics vs Intellia Therapeutics

Black Diamond Therapeutics BDTX · Intellia Therapeutics NTLA · Biotechnology

Black Diamond Therapeutics reported revenue of $70 million in fiscal 2025, about the same as Intellia Therapeutics' $68 million in fiscal 2025. Black Diamond Therapeutics had an operating margin of 17.9%, against -651.7% at Intellia Therapeutics.

Side by side

Black Diamond TherapeuticsIntellia Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$70M$68M
Revenue growth—16.9%
Revenue growth a year, last 5 years—3.1%
Gross margin——
Operating margin17.9%−651.7%
Net margin31.9%−609.9%
Free cash flow—−$396M
Free cash flow margin—−585.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count4.6%9.6%
Last close$1.39$9.52
P/E at the last close——
Insider trades, last 12 months—bought $1.4 million, sold $2.1 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Black Diamond TherapeuticsIntellia Therapeutics
Operating margin
Percent of revenue
Black Diamond TherapeuticsIntellia Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Black Diamond TherapeuticsIntellia Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Black Diamond Therapeutics and Intellia Therapeutics pages.